Latest Opioids Stories
CUPERTINO, Calif., April 24, 2013 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...
MORAGA, Calif., April 22, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be presenting at the 2013 BIO International Convention's BIO Business Forum on April 22(nd), 2013 at the McCormick Place in...
SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve, is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com....
CUPERTINO, Calif., Oct. 30, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 5, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be available by accessing DURECT's homepage at...
Drug testing was used less frequently in Louisiana than recommended by medical treatment guidelines for chronic opioid management, between 23 and 24 percent of cases with longer-term use of narcotics over the study period from 2007/2009 to 2009/2011. Cambridge, MA (PRWEB) October 02, 2012 With opioid misuse a top public health problem in the United States, a new report by the Workers Compensation Research Institute (WCRI) showed that few physicians in Louisiana were following recommended...
This report, Longer-Term Use of Opioids, examined longer-term use of narcotics (or opioids) in 21 states and how often recommended medical treatment guidelines for monitoring injured workers with longer-term use were followed by physicians. However, the study found relatively low compliance with the medical treatment guidelines in most states, including New York. Cambridge, MA (PRWEB) October 02, 2012 With opioid misuse a top public health problem in the United States, a new report by...
Psychological evaluation in Pennsylvania was rarely used among injured workers with longer-term use of narcotics—only 3-4 percent of the workers received the service over the study period from 2007/2009 to 2009/2011. Cambridge, MA (PRWEB) October 02, 2012 With opioid misuse a top public health problem in the United States, a new report by the Workers Compensation Research Institute (WCRI) showed that few physicians in Pennsylvania were following recommended medical treatment guidelines...
SAN FRANCISCO, Sept. 13, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2012 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Wednesday, September 19, 2012 at 10:30 a.m. Eastern time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com....
AACHEN, Germany, September 12, 2012 /PRNewswire/ -- In the first half of 2012 Gruenenthal Group, an international pain therapy expert, reached revenues of EUR473 mn (vs. EUR 483 mn in H1 2011). Corrected by divested businesses, core business grew by 9 per cent in the first half of 2012. Growth was driven by the continued success of Gruenenthal's global pain brands, in particular the strategic growth drivers Palexia(R) (+EUR19 mn) and Versatis(R) (+EUR16 mn) in Europe and...
MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology. Under the terms of the agreement Janssen received a non-exclusive license and other rights to certain Acuform patents. In exchange, Depomed will receive an upfront payment of $10 million and will receive a low single digit royalty on net sales of NUCYNTA® ER (tapentadol...
